The Jerusalem PostPentagon ignored warnings before Iranian drone strike killed six US soldiers, whistleblower allegesInquirer EntertainmentBianca Gonzalez shares how PBB prepares evictees for outside lifeInquirerAnnual 3-month sardine fishing ban starts in Zamboanga PeninsulaDaily MaverickANC cannot renew itself by looking inwards while voters turn awayZDF heuteEntdecken Sie das ZDF-NachrichtenstudioVilaWebLa CUP aposta pel conflicte amb l’estat espanyol com a via d’avenç socialRTL BoulevardACM: Investeerder HAL mag bouwbedrijf VolkerWessels overnemenSRF NewsGlobale Panne – Alter Programmfehler löste Microsoft-Ausfall ausEgypt IndependentTV host Amr Adib comments on Egyptian state selling lands to pay off debtABC NewsWATCH: New video of tanker collision and riverboat sinkingTechCrunchGoogle Maps can now build trip itineraries with real-time details about each stopVanguardASUP declares indefinite strike at Rivers polytechnic
The Daily Newsstand · Free, Always
Monday, November 16, 2026

Jasper Therapeutics reports Q3 results

Translate
  • Jasper Therapeutics press release (JSPR): Q3 Diluted loss per share of $10.19 vs. $32.08 Y/Y.
  • Revenue of $8K, compared with $0 Y/Y.

  • Net loss of $144.5M vs. $18.7M Y/Y, including $129.5M in acquired in-process R&D expense related to the Kira Pharmaceuticals acquisition.

  • Research and development expenses decreased 42% Y/Y to $8.3M.

  • General and administrative expenses increased 33% Y/Y to $6.4M.

  • Cash and cash equivalents totaled $135.3M as of September 30, 2026, compared with $28.7M as of December 31, 2025.

View the original on Seeking Alpha →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.